Recently closed $50 million underwritten offering reinforces strong institutional investor conviction and bolsters balance sheet for execution of second Phase 3 HLP003 trial1- 2,3, EMBRACE, for potent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results